News
Novo Nordisk's fling with Hims & Hers ends in a bust-up
In a statement, Novo Nordisk said that it was terminating the collaboration "due to concerns about their illegal mass compounding and deceptive marketing" of what it claimed were "illegitimate, knockoff versions" of its obesity therapy Wegovy (semaglutide).
11hon MSN
Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...
The loss of Novo’s involvement significantly dented investor confidence in Hims & Hers, plunging shares in the latter by 35% ...
The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...
Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.
Tesla shares rise sharply after the electric-vehicle company launched its highly anticipated robo-taxi service in Austin, ...
Meanwhile, Novo had agreed supply deals with Hims and several of its bigger rivals. The idea was to give their existing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback